Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis

Journal of Neuroimmunology

Volumn 276, Issue 1-2, 2014, Pages 195-201

  Ratzer, R ^a   Romme Christensen, J ^a   Romme Nielsen, B ^a   Sorensen P S ^a   Bornsen L ^a   Sellebjerg, F ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CCR2; CD27; CD38; CD70; CD80; Methylprednisolone; Progressive multiple sclerosis

Indexed keywords

METHYLPREDNISOLONE; ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL ACTIVITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; RELAPSE; TABLET; TH17 CELL; UNSPECIFIED SIDE EFFECT; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; MONONUCLEAR CELL; SEVERITY OF ILLNESS INDEX;

ADULT; ANTI-INFLAMMATORY AGENTS; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX;

EID: 84908500696     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.08.623     Document Type: Article

References (40)

1. Balashov K.E., Smith D.R., Khoury S.J., Hafler D.A., Weiner H.L. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:599-603.
2. Benjamini, Hochberg Controlling the false discovery rate: a practical and powerful approach to multiple testing 1995, 57:289-300.
3. Cazzato G., Mesiano T., Antonello R., Monti F., Carraro N., Torre P., Bosco A., Cargnelutti D. Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur. Neurol. 1995, 35:193-198.
4. Confavreux C., Vukusic S., Moreau T., Adeleine P. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 2000, 343:1430-1438.
5. Correale J., Gilmore W., Li S., Walsh J., Bassani M.M., Lund B., Arias M., Weiner L.P. Resistance to glucocorticoid-induced apoptosis in PLP peptide-specific T cell clones from patients with progressive MS. J. Neuroimmunol. 2000, 109:197-210.
6. Cutter G.R., Baier M.L., Rudick R.A., Cookfair D.L., Fischer J.S., Petkau J., Syndulko K., Weinshenker B.G., Antel J.P., Confavreux C., Ellison G.W., Lublin F., Miller A.E., Rao S.M., Reingold S., Thompson A., Willoughby E. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999, 122:871-882.
7. Fischer J.S., Rudick R.A., Cutter G.R., Reingold S.C. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult. Scler. 1999, 5:244-250.
8. Francosalinas G., Cantaert T., Nolte M.A., Tak P.P., van Lier R.A., Baeten D.L. Enhanced costimulation by CD70+ B cells aggravates experimental autoimmune encephalomyelitis in autoimmune mice. J. Neuroimmunol. 2013, 255:8-17.
9. Frischer J.M., Bramow S., Dal-Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
10. Ganguly D., Haak S., Sisirak V., Reizis B. The role of dendritic cells in autoimmunity. Nat. Rev. Immunol. 2013, 13:566-577.
11. Goodkin D.E., Kinkel R.P., Weinstock-Guttman B., VanderBrug-Medendorp S., Secic M., Gogol D., Perryman J.E., Uccelli M.M., Neilley L. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998, 51:239-245.
12. Hernandes N.A., Wouters E.F., Meijer K., Annegarn J., Pitta F., Spruit M.A. Reproducibility of 6-minute walking test in patients with COPD. Eur. Respir. J. 2011, 38:261-267.
13. Karni A., Abraham M., Monsonego A., Cai G., Freeman G.J., Hafler D., Khoury S.J., Weiner H.L. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. 2006, 177:4196-4202.
14. Kervio G., Carre F., Ville N.S. Reliability and intensity of the six-minute walk test in healthy elderly subjects. Med. Sci. Sports Exerc. 2003, 35:169-174.
15. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu. Rev. Immunol. 2009, 27:485-517.
16. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., Weiner H.L., Nabavi N., Glimcher L.H. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995, 80:707-718.
17. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
18. Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. J. Neurol. Sci. 2013, 333:1-4.
19. Lovett-Racke A.E., Trotter J.L., Lauber J., Perrin P.J., June C.H., Racke M.K. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J. Clin. Invest. 1998, 101:725-730.
20. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
21. Miller S.D., Vanderlugt C.L., Lenschow D.J., Pope J.G., Karandikar N.J., Dal Canto M.C., Bluestone J.A. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 1995, 3:739-745.
22. Racke M.K., Scott D.E., Quigley L., Gray G.S., Abe R., June C.H., Perrin P.J. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J. Clin. Invest. 1995, 96:2195-2203.
23. Ravnborg M., Gronbech-Jensen M., Jonsson A. The MS Impairment Scale: a pragmatic approach to the assessment of impairment in patients with multiple sclerosis. Mult. Scler. 1997, 3:31-42.
24. Ravnborg M., Sorensen P.S., Andersson M., Celius E.G., Jongen P.J., Elovaara I., Bartholome E., Constantinescu C.S., Beer K., Garde E., Sperling B. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010, 9:672-680.
25. Romme Christensen J., Bornsen L., Ratzer R., Piehl F., Khademi M., Olsson T., Sorensen P.S., Sellebjerg F. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, th17- and activated B-cells and correlates with progression. PloS ONE 2013, 8:e57820.
26. Romme Christensen Romme J., Ratzer R., Bornsen L., Lyksborg M., Garde E., Dyrby T.B., Siebner H.R., Sorensen P.S., Sellebjerg F. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology 2014, 82:1499-1507.
27. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., Achiti I., Confavreux C., Coustans M., Le P.E., Edan G., McDonnell G.V., Hawkins S., Trojano M., Liguori M., Cocco E., Marrosu M.G., Tesser F., Leone M.A., Weber A., Zipp F., Miterski B., Epplen J.T., Oturai A., Sorensen P.S., Celius E.G., Lara N.T., Montalban X., Villoslada P., Silva A.M., Marta M., Leite I., Dubois B., Rubio J., Butzkueven H., Kilpatrick T., Mycko M.P., Selmaj K.W., Rio M.E., Sa M., Salemi G., Savettieri G., Hillert J., Compston D.A. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005, 64:1144-1151.
28. Scholz C., Patton K.T., Anderson D.E., Freeman G.J., Hafler D.A. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J. Immunol. 1998, 160:1532-1538.
29. Sellebjerg F., Barnes D., Filippini G., Midgard R., Montalban X., Rieckmann P., Selmaj K., Visser L.H., Sorensen P.S. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur. J. Neurol. 2005, 12:939-946.
30. Skough K., Broman L., Borg K. Test-retest reliability of the 6-min walk test in patients with postpolio syndrome. Int. J. Rehabil. Res. 2013, 36:140-145.
31. Sloka J.S., Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult. Scler. 2005, 11:425-432.
32. Solari A., Radice D., Manneschi L., Motti L., Montanari E. The multiple sclerosis functional composite: different practice effects in the three test components. J. Neurol. Sci. 2005, 228:71-74.
33. Sorensen T.L., Sellebjerg F. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology 2001, 57:1371-1376.
34. Sorensen P.S., Mellgren S.I., Svenningsson A., Elovaara I., Frederiksen J.L., Beiske A.G., Myhr K.M., Sogaard L.V., Olsen I.C., Sandberg-Wollheim M. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol. 2009, 8:519-529.
35. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
36. Stys P.K., Zamponi G.W., van MJ, Geurts J.J. Will the real multiple sclerosis please stand up?. Nat. Rev. Neurosci. 2012, 20(13):507-514.
37. Tang Q., Henriksen K.J., Boden E.K., Tooley A.J., Ye J., Subudhi S.K., Zheng X.X., Strom T.B., Bluestone J.A. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J. Immunol. 2003, 171:3348-3352.
38. Ukkonen M., Wu K., Reipert B., Dastidar P., Elovaara I. Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis. Mult. Scler. 2007, 13:701-707.
39. Weiner H.L. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J. Neurol. 2008, 255(Suppl. 1):3-11.
40. Zivadinov R., Rudick R.A., De M.R., Nasuelli D., Ukmar M., Pozzi-Mucelli R.S., Grop A., Cazzato G., Zorzon M. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001, 57:1239-1247.